Expand CRBP Menu
CRBP MENU

CRBP Latest Press Releases

-- April 2, 2024 --

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC Globe Newswire 8:00 AM

-- March 12, 2024 --

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update Globe Newswire 8:00 AM

-- March 6, 2024 --

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit Globe Newswire 8:00 AM

-- February 28, 2024 --

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer Globe Newswire 8:00 AM

-- February 6, 2024 --

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference Globe Newswire 9:50 AM

-- February 2, 2024 --

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares Globe Newswire 4:01 PM

-- January 31, 2024 --

Corbus Pharmaceuticals Announces Pricing of Public Offering Globe Newswire 9:19 AM

-- January 30, 2024 --

Corbus Pharmaceuticals Announces Proposed Public Offering Globe Newswire 6:55 PM

-- January 26, 2024 --

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024 Globe Newswire 7:30 AM

-- January 23, 2024 --

Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU Globe Newswire 8:00 AM

-- January 9, 2024 --

Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-av8 monoclonal antibody (CRB-601) Globe Newswire 8:00 AM

-- December 18, 2023 --

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU Globe Newswire 8:00 AM